NextCure targeted in cancer drug trade secrets suit

Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

16 November 2021 Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

Generics

Delhi court approves Natco generic of Novartis cancer drug

29 August 2019 The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

NextCure targeted in cancer drug trade secrets suit

More on this story

Editor's picks

Editor's picks

More features